Status:
COMPLETED
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Lead Sponsor:
Eli Lilly and Company
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
Eligibility Criteria
Inclusion
- Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
- Have venous access sufficient to allow for blood sampling
- Are able to swallow oral medication
Exclusion
- Have any other skin conditions, excluding plaque psoriasis
- Have a current or recent acute, active infection
- Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
- Are lactating or breastfeeding women
Key Trial Info
Start Date :
December 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 6 2025
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT06176768
Start Date
December 6 2023
End Date
May 6 2025
Last Update
October 15 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Research Associates
Los Angeles, California, United States, 90045
2
Clinical Science Institute
Santa Monica, California, United States, 90404
3
Driven Research
Coral Gables, Florida, United States, 33134
4
Conquest Research
Winter Park, Florida, United States, 32789